Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 20/20 | 0.64 |
| ▸ | PLA2G7 | Q13093 | 4/20 | 0.61 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15101009 | 0.88 | MGLL (0.63) | MGLLPLA2G7ABHD6 | |
| SCHEMBL18074105 | 0.87 | MGLL (0.62) | MGLLPLA2G7ABHD6 | |
| SCHEMBL15100943 | 0.87 | MGLL (0.62) | MGLLPLA2G7ABHD6 | |
| SCHEMBL15094316 | 0.86 | MGLL (0.61) | MGLLPLA2G7ABHD6 | |
| SCHEMBL18064870 | 0.86 | MGLL (0.60) | MGLLPLA2G7ABHD6 | |
| SCHEMBL22365045 | 0.86 | MGLL (0.64) | MGLLPLA2G7ABHD6 | |
| SCHEMBL15100867 | 0.84 | MGLL (0.61) | MGLLPLA2G7ABHD6 | |
| SCHEMBL18634145 | 0.84 | MGLL (0.59) | MGLLPLA2G7ABHD6 | |
| SCHEMBL15094091 | 0.83 | MGLL (0.58) | MGLLPLA2G7ABHD6 | |
| SCHEMBL15093714 | 0.83 | ALDH1A1 (0.54) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188793-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 2021-06-24 | — | — | US | claimed |
| EP-2800565-B1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-03-25 | — | — | EP | claimed |
| US-20180208568-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2018-07-26 | — | — | US | claimed |
| US-12018004-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2024-06-25 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-11530189-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECKA/S (DK) | 2022-12-20 | — | — | US | disclosed |
| US-11530189-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECKA/S (DK) | 2022-12-20 | — | — | US | disclosed |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| US-9133148-B2 | Carbamate compounds and of making and using same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133148-B2 | Carbamate compounds and of making and using same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133148-B2 | Carbamate compounds and of making and using same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150148330-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2015-05-28 | — | — | US | disclosed |
| US-20150148330-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2015-05-28 | — | — | US | disclosed |
| US-20150148330-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2015-05-28 | — | — | US | disclosed |
| EP-2800565-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2014-11-12 | — | — | EP | disclosed |
| WO-2013103973-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-07-11 | — | — | WO | disclosed |
| WO-2013103973-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530189-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | MGLL 54/4885PLA2G7 195/4885ABHD6 1/4885 |
| US-20210188793-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | MGLL 54/4885PLA2G7 195/4885ABHD6 1/4885 |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | MGLL, LIPA, PNLIP | MGLL 1/4885PLA2G7 141/4885ABHD6 49/4885 |
| US-20180208568-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, NCEH1 | MGLL 14/4885PLA2G7 277/4885ABHD6 1/4885 |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | MGLL 54/4885PLA2G7 195/4885ABHD6 1/4885 |
| US-20150148330-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABHD6, ABHD16A, PRMT6 | MGLL 16/4885PLA2G7 320/4885ABHD6 1/4885 |
| US-12018004-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | MGLL 54/4885PLA2G7 195/4885ABHD6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.